News + Resources

Keep up with the latest

Featured

This Scientist Is Building Custom Gene-Editing Tools

Scribe Therapeutics Reports Preclinical Data Validating its CRISPR Genome Editing and Epigenome Modifying Technologies for Addressing Cardiometabolic Disease at American Heart Association (AHA) Scientific Sessions 2024

November 25, 2024

Scribe Therapeutics Reports Preclinical Data Validating its CRISPR Genome Editing and Epigenome Modifying Technologies for Addressing Cardiometabolic Disease at American Heart Association (AHA) Scientific Sessions 2024

November 25, 2024

CRISPR 2.0, the Next Generation

June 21, 2024

Aspen Ideas: Health

CRISPR 2.0, the Next Generation

June 21, 2024

The Age of CRISPR: Engineering the Future of Genetic Medicine

February 23, 2024

TEDxBerkeley

The Age of CRISPR: Engineering the Future of Genetic Medicine

February 23, 2024

Scribe Therapeutics Picks Cholesterol-Lowering As First In Vivo Gene Target

February 7, 2024

Scrip

Scribe Therapeutics Picks Cholesterol-Lowering As First In Vivo Gene Target

February 7, 2024

All Stories

News

Scribe, Vertex add to gene therapy's advance with $1B+ deal, near-term BLA

September 27, 2022

BioWorld

Read Now

Press Release

Scribe, Vertex add to gene therapy's advance with $1B+ deal, near-term BLA

September 27, 2022

BioWorld

Read Now

News

Sanofi ThiNKs Scribe’s CRISPR Approach Can Advance Its NK Cell Therapy Goals

September 27, 2022

Scrip

Read Now

Press Release

Sanofi ThiNKs Scribe’s CRISPR Approach Can Advance Its NK Cell Therapy Goals

September 27, 2022

Scrip

Read Now

News

Sanofi’s NK cell toolbox grows with Scribe’s next-gen editor

September 27, 2022

BioCentury

Read Now

Press Release

Sanofi’s NK cell toolbox grows with Scribe’s next-gen editor

September 27, 2022

BioCentury

Read Now

News

Natural killers gain more attention with major Franco-US collab

September 27, 2022

The Pharma Letter

Read Now

Press Release

Natural killers gain more attention with major Franco-US collab

September 27, 2022

The Pharma Letter

Read Now

News

Sanofi partners with Scribe to gain gene editing tools for cell therapy work

September 27, 2022

Biopharma Dive

Read Now

Press Release

Sanofi partners with Scribe to gain gene editing tools for cell therapy work

September 27, 2022

Biopharma Dive

Read Now

News

Sanofi turns to a Jennifer Doudna gene editing upstart for next-gen NK cell alliance

September 27, 2022

Endpoints News

Read Now

Press Release

Sanofi turns to a Jennifer Doudna gene editing upstart for next-gen NK cell alliance

September 27, 2022

Endpoints News

Read Now

News

Biogen takes another dip into Scribe gene therapy collab with another disease target

May 2, 2022

Fierce Biotech

Read Now

News

Biogen, Scribe to develop additional gene therapy disease target

May 2, 2022

Seeking Alpha

Read Now

News

40 Under 40: Benjamin Oakes, Scribe Therapeutics

April 22, 2022

San Francisco Business Times

Read Now

News

Future of Genetic Medicine w/ Scribe Therapeutics Founders

April 11, 2022

BIOS

Read Now

News

The Science of CRISPR with Dr. Benjamin Oakes

April 4, 2022

Science in Society

Read Now

News

CFOs On the Move

March 26, 2022

CFO

Read Now

Press release

Scribe Achieves Milestone for In Vivo Program in Collaboration with Prevail Therapeutics, a part of Lilly’s Gene Therapy Division, and Announces ASGCT Joint Presentation on Self-Inactivating AAV Technology for Neurological and Neuromuscular Disorders

April 28, 2025

Read Now

Press release

Scribe Therapeutics to Unveil Latest Preclinical Data on Proprietary CRISPR Epigenetic Silencing Technology for LDL-C Lowering at the 2025 EAS Congress

April 23, 2025

Read Now

Press release

Scribe Therapeutics Presents Data on its Epigenetic Long-Term X-Repressor Technology at the 2025 Keystone Symposia on Precision Genome Engineering Conference

March 7, 2025

Read Now

Press release

Scribe Therapeutics to Participate in Upcoming Conferences

February 26, 2025

Read Now

Press release

Scribe Therapeutics Achieves Milestone for In Vivo Program in Collaboration with Sanofi

January 13, 2025

Read Now

Press release

Scribe Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

January 9, 2025

Read Now

Publications and presentations

Presentation

Scribe Corporate Deck 2025 Q1

February 3, 2025

Read Now

Publication

CasX enzymes comprise a distinct family of RNA-guided genome editors

February 4, 2019

Nature

Read Now

Publication

Efficient genome editing in the mouse brain by local delivery of engineered Cas9 ribonucleoprotein complexes

May 1, 2017

Nature Biotechnology

Read Now

Publication

Targeted gene knock-in by homology-directed genome editing using Cas9 ribonucleoprotein and AAV donor delivery

March 2, 2017

Nucleic Acids Research

Read Now

Publication

Profiling of engineering hotspots identifies an allosteric CRISPR-Cas9 switch

June 1, 2016

Nature Biotechnology

Read Now

Publication

Multi-reporter selection for the design of active and more specific zinc-finger nucleases for genome editing

January 7, 2016

Nature Communications

Read Now

Publication

Enhanced homology-directed human genome engineering by controlled timing of CRISPR/Cas9 delivery

December 15, 2014

eLife

Read Now

Publication

Programmable RNA recognition and cleavage by CRISPR/Cas9

December 11, 2014

Nature

Read Now

Publication

MicroRNA-mediated switching of chromatin-remodelling complexes in neural development

July 30, 2009

Nature

Read Now